Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

According to DelveInsight's analysis, the market for facioscapulohumeral muscular dystrophy is anticipated to increase during the forecast period (2025-2034), owing to improved diagnosis, treatment ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...